Mentions
Extended reach
Total likes
Video views
AI synopsis
The collective discourse reflects strong consensus on the study’s promising results, exemplified by phrases like 'large improvements' and 'reduces risk,' while users actively analyze trial data and speculate on clinical significance, driven by an informative and optimistic tone.
Most discussions support the positive findings of the publication, emphasizing improvements in potassium management with SZC.
The discussions demonstrate high curiosity, with many exploring specific trial results and clinical implications.
Comments reference detailed outcomes, such as OR values and safety profiles, indicating active engagement.
The posts highlight significant clinical advances, including better MRA use and hyperkalemia control, suggesting high real-world impact.
Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart Failure
Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With HF SZC led to large improvements in percentage of participants with normokalemia while on optimal spironolactone dose https://t.co/BTY2ocbSyz https://t.co/WbTDVDeZEO
#REALIZE-K Trial: Sodium Zirconium Cyclosilicate for Management of #Hyperkalemia During Spironolactone Optimization in Patients with #HeartFailure
REALIZE the fact that lowering plasma potassium levels is no guarantee of reducing cardiovascular risk. @JavedButler1's 2023 DIAMOND study findings are impressively confirmed by @MkosiborodMD & co-workers' REALIZE-K. https://t.co/YAOErv0Loh https://t.co/wSk4hGoqya
Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart Failure “Although underpowered for clinical outcomes, more participants had HF events with SZC than placebo” https://t.co/ZuyCkuQiCx https://t.co/uge04bkAEZ
This video discusses the REALIZEK study, which shows that sodium zirconium cyclosilicate helps manage hyperkalemia, allowing safe spironolactone use in heart failure patients with reduced ejection fraction.
This week, we discuss resistant hypertension, potassium binders for MRA use in heart failure, and a positive study for vitamin D. The abstract highlights the role of sodium zirconium cyclosilicate in managing…
ロケルマ（SZC）とスピロノラクトンのRCT J Am Coll Cardiol. 2025 Mar 18;85(10):971-984. HFrEF高K血症でSZCはスピロノラクトン維持を促進、至適反応71% vs36%(OR4.45,P<0.001)、高K発現半減(HR0.51)、減量/中止抑制(HR0.37)。一方でHFイベントはSZC多(11% vs3%)。 https://t.co/PRNJhCulCe
@CardioSM 私も実際はそこまで気にしていないのですが、Realize-K trialでちょっと心不全増えるかもsignalがでているのもあって、どうせならビルタサでいいんじゃねというのが今の気持ちです。Pも下げるらしいとなってますがここは実際どうなんでしょ? https://t.co/3Q0R1Vz7X0
RT @drbennisahmed: Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With HF…
RT @gunnar_heine: REALIZE the fact that lowering plasma potassium levels is no guarantee of reducing cardiovascular risk. @JavedButler1's 2…
RT @drbennisahmed: Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With HF…
RT @PharmacistHF: Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart F…
RT @PharmacistHF: Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart F…
RT @drbennisahmed: Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With HF…
RT @gunnar_heine: REALIZE the fact that lowering plasma potassium levels is no guarantee of reducing cardiovascular risk. @JavedButler1's 2…
RT @drbennisahmed: Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With HF…
RT @gunnar_heine: REALIZE the fact that lowering plasma potassium levels is no guarantee of reducing cardiovascular risk. @JavedButler1's 2…
RT @mi_cardiologo:
RT @PharmacistHF: Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart F…
RT @drbennisahmed: Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With HF…
RT @drbennisahmed: Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With HF…
RT @mi_cardiologo:
Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart Failure | JACC https://t.co/vY6bEgLnEC ✅The SZC + spironolactone combo... balancing effectiveness and risks ✅Any direct Effect of SZC on heart? #cardiology
RT @drbennisahmed: Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With HF…
RT @drbennisahmed: Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With HF…
RT @drbennisahmed: Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With HF…
RT @gunnar_heine: REALIZE the fact that lowering plasma potassium levels is no guarantee of reducing cardiovascular risk. @JavedButler1's 2…
RT @PharmacistHF: Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart F…
RT @drbennisahmed: Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With HF…
RT @gunnar_heine: REALIZE the fact that lowering plasma potassium levels is no guarantee of reducing cardiovascular risk. @JavedButler1's 2…
RT @gunnar_heine: REALIZE the fact that lowering plasma potassium levels is no guarantee of reducing cardiovascular risk. @JavedButler1's 2…
RT @gunnar_heine: REALIZE the fact that lowering plasma potassium levels is no guarantee of reducing cardiovascular risk. @JavedButler1's 2…
RT @drbennisahmed: Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With HF…
RT @mi_cardiologo:
RT @gunnar_heine: REALIZE the fact that lowering plasma potassium levels is no guarantee of reducing cardiovascular risk. @JavedButler1's 2…
RT @drbennisahmed: Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With HF…
RT @drbennisahmed: Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With HF…
Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With HF SZC led to large improvements in percentage of participants with normokalemia while on optimal spironolactone dose https://t.co/BTY2ocbSyz https://t.co/WbTDVDeZEO
RT @gunnar_heine: REALIZE the fact that lowering plasma potassium levels is no guarantee of reducing cardiovascular risk. @JavedButler1's 2…
Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart Failure “Although underpowered for clinical outcomes, more participants had HF events with SZC than placebo” https://t.co/ZuyCkuQiCx https://t.co/uge04bkAEZ
RT @gunnar_heine: REALIZE the fact that lowering plasma potassium levels is no guarantee of reducing cardiovascular risk. @JavedButler1's 2…
RT @gunnar_heine: REALIZE the fact that lowering plasma potassium levels is no guarantee of reducing cardiovascular risk. @JavedButler1's 2…
Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart Failure | JACC https://t.co/ZZU5Fd3uMh
Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart Failure | JACC
RT @gunnar_heine: REALIZE the fact that lowering plasma potassium levels is no guarantee of reducing cardiovascular risk. @JavedButler1's 2…
REALIZE the fact that lowering plasma potassium levels is no guarantee of reducing cardiovascular risk. @JavedButler1's 2023 DIAMOND study findings are impressively confirmed by @MkosiborodMD & co-workers' REALIZE-K. https://t.co/YAOErv0Loh https://t.co/wSk4hGoqya
RT @accpcardprn: Who’s using potassium binders in their hyperkalemic HFrEF patients
Who’s using potassium binders in their hyperkalemic HFrEF patients
Need clinical outcomes... what makes the pop of pts that can't tolerate MRA 2/2 HyperK different? does K-binding, which allows for GDMT optimization make a clinical difference? https://t.co/ftpADagf90
Sodium Zirconium Cyclosilicate helps manage high potassium levels during Spironolactone optimization in heart failure patients. #HeartHealth #MedicalResearch https://t.co/PpY9Zhjx5Q https://t.co/BZ4HAfIPSJ
الصوديوم زركونيوم سيكلوسيليكات يساعد في إدارة مستويات البوتاسيوم العالية أثناء تحسين سبيرونولاكتون في مرضى فشل القلب. #صحة_القلب #البحث_الطبي https://t.co/xw1F5WKgVV https://t.co/YoK3zkhIje
＃循薬ネット Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart Failure https://t.co/qOunONQN6I
Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With H… https://t.co/Sw4k51pw6r
RT @ValleAlfonso: Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart F…
RT @ValleAlfonso: Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart F…
RT @ValleAlfonso: Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart F…
RT @ValleAlfonso: Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart F…
Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart Failure | Journal of the American College of Cardiology https://t.co/tj3JdEkTKy
RT @ValleAlfonso: Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart F…
RT @ValleAlfonso: Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart F…
RT @ValleAlfonso: Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart F…
RT @ValleAlfonso: Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart F…
RT @ValleAlfonso: Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart F…
RT @ValleAlfonso: Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart F…
RT @ValleAlfonso: Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart F…
RT @ValleAlfonso: Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart F…
RT @ValleAlfonso: Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart F…
RT @ValleAlfonso: Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart F…
RT @ValleAlfonso: Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart F…
RT @ValleAlfonso: Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart F…
RT @ValleAlfonso: Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart F…
RT @ValleAlfonso: Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart F…
RT @ValleAlfonso: Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart F…
RT @ValleAlfonso: Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart F…
RT @ValleAlfonso: Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart F…
RT @ValleAlfonso: Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart F…
Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With HF SZC led to large improvements in the percentage of participants with normokalemia while on optimal spironolactone dose https://t.co/BTY2ocbSyz https://t.co/m4XXAou66d
RT @ValleAlfonso: Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart F…
RT @ValleAlfonso: Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart F…
RT @ValleAlfonso: Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart F…
RT @ValleAlfonso: Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart F…
Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart Failure
RT @drbennisahmed: Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients with Heart…
RT @drbennisahmed: Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients with Heart…
RT @drbennisahmed: Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients with Heart…
RT @drbennisahmed: Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients with Heart…
RT @drbennisahmed: Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients with Heart…
RT @drbennisahmed: Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients with Heart…
Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients with Heart Failure SZC led to large improvements in the percentage of participants with normokalemia while on optimal spironolactone dose https://t.co/BTY2ocbSyz https://t.co/JMvPMoU3w9
2024 best publications in heart failure Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients with HF SZC led to large improvements in percentage of normokalemia on optimal spironolactone dose https://t.co/BTY2ocbkJ1 https://t.co/SKtrB6TZdn
RT @JuliaSellerm: 8️⃣ Other Comorbidities
8️⃣ Other Comorbidities
Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart Failure https://t.co/ghfSD80R3c via @practiceupdate
HFrEFの患者に対して、スピロノラクトンとSZCを併用した場合、スピの至適な投与は71%vs36%で有意に併用群の方が継続して使えるかもしれない。 OR：4.45（95% CI 2.89-6.86）P< 0.001 https://t.co/5o2GPBpxGW
Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization Patients with HF SZC led to improvements in percentage of participants with normokalemia while on optimal spironolactone , and reduced risk of hyperkalaemia https://t.co/BTY2ocbkJ1 https://t.co/b1welGKzZ3
Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients with Heart Failure | Journal of the American College of Cardiology https://t.co/0cj23LrAfK
Significant increase in the number of #HFrEF patients on spironolactone >/= 25 mg/day and normokalaemia while on #SZC in #REALIZE_K @AHA2024 @JACCJournals @MkosiborodMD @markcpetrie20 #Iain_Squire @BSHeartFailure #CardioTwitter https://t.co/hxMp7yEVJC
RT @JACCJournals: Dr. @MkosiborodMD on REALIZE-K trial: In participants w/ symptomatic #HFrEF & hyperkalemia (HK), SZC ➡️ large improvement…
RT @HanCardiomd: #REALIZE-K Trial: Sodium Zirconium Cyclosilicate for Management of #Hyperkalemia During Spironolactone Optimization in Pat…
RT @ValleAlfonso:
RT @HanCardiomd: #REALIZE-K Trial: Sodium Zirconium Cyclosilicate for Management of #Hyperkalemia During Spironolactone Optimization in Pat…
RT @HanCardiomd: #REALIZE-K Trial: Sodium Zirconium Cyclosilicate for Management of #Hyperkalemia During Spironolactone Optimization in Pat…
RT @HanCardiomd: #REALIZE-K Trial: Sodium Zirconium Cyclosilicate for Management of #Hyperkalemia During Spironolactone Optimization in Pat…
#AHA24 ICYMI: #JACC AE Dr. @MKIttlesonMD & Dr. @MkosiborodMD discuss the trial design of the REALIZE-K trial that looked at sodium zirconium cyclosilicate to reduce the risk of hyperkalemia in #heartfailure patients
RT @HanCardiomd: #REALIZE-K Trial: Sodium Zirconium Cyclosilicate for Management of #Hyperkalemia During Spironolactone Optimization in Pat…
RT @ValleAlfonso:
RT @JACCJournals: Dr. @MkosiborodMD on REALIZE-K trial: In participants w/ symptomatic #HFrEF & hyperkalemia (HK), SZC ➡️ large improvement…
RT @HanCardiomd: #REALIZE-K Trial: Sodium Zirconium Cyclosilicate for Management of #Hyperkalemia During Spironolactone Optimization in Pat…
RT @HanCardiomd: #REALIZE-K Trial: Sodium Zirconium Cyclosilicate for Management of #Hyperkalemia During Spironolactone Optimization in Pat…
RT @ValleAlfonso:
RT @HanCardiomd: #REALIZE-K Trial: Sodium Zirconium Cyclosilicate for Management of #Hyperkalemia During Spironolactone Optimization in Pat…
RT @ValleAlfonso:
RT @HanCardiomd: #REALIZE-K Trial: Sodium Zirconium Cyclosilicate for Management of #Hyperkalemia During Spironolactone Optimization in Pat…
RT @ValleAlfonso:
RT @HanCardiomd: #REALIZE-K Trial: Sodium Zirconium Cyclosilicate for Management of #Hyperkalemia During Spironolactone Optimization in Pat…
RT @HanCardiomd: #REALIZE-K Trial: Sodium Zirconium Cyclosilicate for Management of #Hyperkalemia During Spironolactone Optimization in Pat…
RT @ValleAlfonso:
#REALIZE-K Trial: Sodium Zirconium Cyclosilicate for Management of #Hyperkalemia During Spironolactone Optimization in Patients with #HeartFailure SZC optimizes spironolactone use safely in #HFrEF. #CardioSky www.jacc.org/doi/10.1016/... @accintouch.bsky.social
#REALIZE-K Trial: Sodium Zirconium Cyclosilicate for Management of #Hyperkalemia During Spironolactone Optimization in Patients with #HeartFailure
RT @ValleAlfonso:
RT @ValleAlfonso:
RT @ValleAlfonso:
Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients with Heart Failure #AHA24 #JACC #CardioSky #MedSky @jaccjournals.bsky.social @ahascience.bsky.social www.jacc.org/doi/10.1016/...
Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization HF SZC led to large improvements in the percentage of participants with normokalemia while on optimal spironolactone dose, and reduced risk of hyperkalaemia https://t.co/BTY2ocbkJ1 https://t.co/gET7IYV1db
RT @JACCJournals: Dr. @MkosiborodMD on REALIZE-K trial: In participants w/ symptomatic #HFrEF & hyperkalemia (HK), SZC ➡️ large improvement…
RT @JACCJournals: Dr. @MkosiborodMD on REALIZE-K trial: In participants w/ symptomatic #HFrEF & hyperkalemia (HK), SZC ➡️ large improvement…
Dr. @MkosiborodMD on REALIZE-K trial: In participants w/ symptomatic #HFrEF & hyperkalemia (HK), SZC ➡️ large improvements in optimizing use & dose of MRA & K* levels, &
JACC. 2025 Mar, 85 (10) 971–984. DOI: 10.1016/j.jacc.2024.11.014. Aprender é um ato de empatia com o futuro. číst dál. Zobrazit všech 5 komentářů. před 3 d.
2025; DOI: https://doi.org/10.1016/j.jacc.2024.11.014 · 2024 VA/DOD Clinical Practice Guideline for Stroke Rehabilitation. 26 Jan, 2025 | 17:07h | UTC.
2025; DOI: https://doi.org/10.1016/j.jacc.2024.11.014 · Phase 2b RCT: Abelacimab Significantly Reduces Bleeding Events Compared with Rivaroxaban in Patients ...
org/10.1016/j.jacc.2023.12.023. genannt Bonsmann S. Socio-demographic and ... https://doi.org/10.1016/j.jand.2024.11.014. [276] Chen AS, Borden CG ...
Source: jacc.org/doi/10.1016/j.jacc.2024.11.014. Related Posts. They Said What?!? Conversations With Key Cardiologists. Teresa Sellinger Cardiology-Featured ...
2025; DOI: https://doi.org/10.1016/j.jacc.2024.11.014 · Review: Heart Failure with Preserved Ejection Fraction. 9 Jan, 2025 | 11:42h | UTC. Introduction: This ...
2025; DOI: https://doi.org/10.1016/j.jacc.2024.11.014 · Phase 2b RCT: Abelacimab Significantly Reduces Bleeding Events Compared with Rivaroxaban in Patients ...
2025; DOI: https://doi.org/10.1016/j.jacc.2024.11.014 · Multidrug-resistant Gram-negative bacterial infections: Key Updates and Practical Strategies. 25 Jan ...
2025; DOI: https://doi.org/10.1016/j.jacc.2024.11.014 · Phase 2b RCT: Abelacimab Significantly Reduces Bleeding Events Compared with Rivaroxaban in Patients ...
2025; DOI: https://doi.org/10.1016/j.jacc.2024.11.014 · Phase 2b RCT: Abelacimab Significantly Reduces Bleeding Events Compared with Rivaroxaban in Patients ...
2025; DOI: https://doi.org/10.1016/j.jacc.2024.11.014 · Multidrug-resistant Gram-negative bacterial infections: Key Updates and Practical Strategies. 25 Jan ...
2025; DOI: https://doi.org/10.1016/j.jacc.2024.11.014 · SR: Lower BP Targets Reduce Stroke Risk and Cardiovascular Events in Older Adults. 16 Jan, 2025 | 12 ...
2025; DOI: https://doi.org/10.1016/j.jacc.2024.11.014 · Phase 2b RCT: Abelacimab Significantly Reduces Bleeding Events Compared with Rivaroxaban in Patients ...
Not All Hospitalized Heart Failure Patients Are the Same: A New Worldview @JACCJournals https://www.jacc.org/doi/10.1016/j.jchf.2024.11.014.
Not All Hospitalized Heart Failure Patients Are the Same: A New Worldview @JACCJournals https://www.jacc.org/doi/10.1016/j.jchf.2024.11.014.
Not All Hospitalized Heart Failure Patients Are the Same: A New Worldview @JACCJournals https://www.jacc.org/doi/10.1016/j.jchf.2024.11.014.
doi:10.1016/j.jacc.2023.10.039. doi:10.1016/j.ahj.2024.11.014. doi:10.1016/j.jacc.2009.07.057. #cholesterol · original sound - Kristen Blake ...
jacc.2023.10.039. doi:10.1016/j.ahj.2024.11.014. doi:10.1016/j.jacc.2009.07.057.
Not All Hospitalized Heart Failure Patients Are the Same: A New Worldview @JACCJournals https://www.jacc.org/doi/10.1016/j.jchf.2024.11.014.
https://www.jacc.org/doi/10.1016/j.jacc. 2025.11.027?utm_medium ... jacc.org/doi/10.1016/j.jchf.2024.11.014 · May be an image of text.
doi:10.1016/j.jacc.2023.10.039. doi:10.1016/j.ahj.2024.11.014. doi:10.1016/j.jacc.2009.07.057. #cholesterol · original sound - Kristen Blake ...
Not All Hospitalized Heart Failure Patients Are the Same: A New Worldview @JACCJournals https://www.jacc.org/doi/10.1016/j.jchf.2024.11.014.
Not All Hospitalized Heart Failure Patients Are the Same: A New Worldview @JACCJournals https://www.jacc.org/doi/10.1016/j.jchf.2024.11.014.
JACC. 2025 Mar, 85 (10) 971–984. DOI: 10.1016/j.jacc.2024.11.014. Aprender é um ato de empatia com o futuro. more. View all 5 comments. June ...
Not All Hospitalized Heart Failure Patients Are the Same: A New Worldview @JACCJournals https://www.jacc.org/doi/10.1016/j.jchf.2024.11.014.
Not All Hospitalized Heart Failure Patients Are the Same: A New Worldview @JACCJournals https://www.jacc.org/doi/10.1016/j.jchf.2024.11.014.
... Heart Failure JACC. 2025 Mar, 85 (10) 971–984 DOI: 10.1016/j.jacc.2024.11.014 Aprender é um ato de empatia com o futuro.".
Not All Hospitalized Heart Failure Patients Are the Same: A New Worldview @JACCJournals https://www.jacc.org/doi/10.1016/j.jchf.2024.11.014.
JACC. 2025 Mar, 85 (10) 971–984. DOI: 10.1016/j.jacc.2024.11.014. Aprender é um ato de empatia com o futuro. more. View all 5 comments. 4 ...
Not All Hospitalized Heart Failure Patients Are the Same: A New Worldview @JACCJournals https://www.jacc.org/doi/10.1016/j.jchf.2024.11.014.
Not All Hospitalized Heart Failure Patients Are the Same: A New Worldview @JACCJournals https://www.jacc.org/doi/10.1016/j.jchf.2024.11.014.
JACC. 2025 Mar, 85 (10) 971–984. DOI: 10.1016/j.jacc.2024.11.014. Aprender é um ato de empatia com o futuro. more. View all 5 comments. June ...
JACC. 2025 Mar, 85 (10) 971–984. DOI: 10.1016/j.jacc.2024.11.014. Aprender é um ato de empatia com o futuro. more. View all 5 comments. June ...
JACC. 2025 Mar, 85 (10) 971–984. DOI: 10.1016/j.jacc.2024.11.014. Aprender é um ato de empatia com o futuro. more. View all 5 comments. June ...
JACC. 2025 Mar, 85 (10) 971–984. DOI: 10.1016/j.jacc.2024.11.014. Aprender é um ato de empatia com o futuro. more. View all 5 comments. June ...
JACC. 2025 Mar, 85 (10) 971–984. DOI: 10.1016/j.jacc.2024.11.014. Aprender é um ato de empatia com o futuro. more. View all 5 comments. June ...
https://www.jacc.org/doi/10.1016/j.jacc. 2025.11.027?utm_medium ... jacc.org/doi/10.1016/j.jchf.2024.11.014 · May be an image of text.
JACC. 2025 Mar, 85 (10) 971–984. DOI: 10.1016/j.jacc.2024.11.014. Aprender é um ato de empatia com o futuro. more. View all 5 comments. June ...
Not All Hospitalized Heart Failure Patients Are the Same: A New Worldview @JACCJournals https://www.jacc.org/doi/10.1016/j.jchf.2024.11.014.
JACC. 2025 Mar, 85 (10) 971–984. DOI: 10.1016/j.jacc.2024.11.014. Aprender é um ato de empatia com o futuro. more. View all 5 comments. June ...
Not All Hospitalized Heart Failure Patients Are the Same: A New Worldview @JACCJournals https://www.jacc.org/doi/10.1016/j.jchf.2024.11.014.
https://www.jacc.org/doi/10.1016/j.jacc. 2025.11.027?utm_medium ... jacc.org/doi/10.1016/j.jchf.2024.11.014 · May be an image of text.
Not All Hospitalized Heart Failure Patients Are the Same: A New Worldview @JACCJournals https://www.jacc.org/doi/10.1016/j.jchf.2024.11.014.
Not All Hospitalized Heart Failure Patients Are the Same: A New Worldview @JACCJournals https://www.jacc.org/doi/10.1016/j.jchf.2024.11.014.
Not All Hospitalized Heart Failure Patients Are the Same: A New Worldview @JACCJournals https://www.jacc.org/doi/10.1016/j.jchf.2024.11.014.
Not All Hospitalized Heart Failure Patients Are the Same: A New Worldview @JACCJournals https://www.jacc.org/doi/10.1016/j.jchf.2024.11.014.
Not All Hospitalized Heart Failure Patients Are the Same: A New Worldview @JACCJournals https://www.jacc.org/doi/10.1016/j.jchf.2024.11.014.
Not All Hospitalized Heart Failure Patients Are the Same: A New Worldview @JACCJournals https://www.jacc.org/doi/10.1016/j.jchf.2024.11.014.
https://www.jacc.org/doi/10.1016/j.jacc. 2025.11.027?utm_medium ... jacc.org/doi/10.1016/j.jchf.2024.11.014 · May be an image of text.
2025; DOI: https://doi.org/10.1016/j.jacc.2024.11.014. Join LinksMedicus' Telegram Channels and WhatsApp Alerts for personalized updates in ...
Not All Hospitalized Heart Failure Patients Are the Same: A New Worldview @JACCJournals https://www.jacc.org/doi/10.1016/j.jchf.2024.11.014.
JACC. 2025 Mar, 85 (10) 971–984. DOI: 10.1016/j.jacc.2024.11.014. Aprender é um ato de empatia com o futuro. 更多. 全部5条评论. 6月24日.
Not All Hospitalized Heart Failure Patients Are the Same: A New Worldview @JACCJournals https://www.jacc.org/doi/10.1016/j.jchf.2024.11.014.
Not All Hospitalized Heart Failure Patients Are the Same: A New Worldview @JACCJournals https://www.jacc.org/doi/10.1016/j.jchf.2024.11.014.
Not All Hospitalized Heart Failure Patients Are the Same: A New Worldview @JACCJournals https://www.jacc.org/doi/10.1016/j.jchf.2024.11.014.
JACC. 2025 Mar, 85 (10) 971–984. DOI: 10.1016/j.jacc.2024.11.014. Aprender é um ato de empatia com o futuro. more. View all 5 comments. June ...
Not All Hospitalized Heart Failure Patients Are the Same: A New Worldview @JACCJournals https://www.jacc.org/doi/10.1016/j.jchf.2024.11.014.
... 2024.11.014 AF in AHF @escardio https://journals.sagepub.com ... https://www.jacc.org/doi/10.1016/j.jacc.2021.12.012 · May be an image ...
https://www.jacc.org/doi/10.1016/j.jacc. 2025.11.027?utm_medium ... jacc.org/doi/10.1016/j.jchf.2024.11.014 · May be an image of text.
Not All Hospitalized Heart Failure Patients Are the Same: A New Worldview @JACCJournals https://www.jacc.org/doi/10.1016/j.jchf.2024.11.014.
Not All Hospitalized Heart Failure Patients Are the Same: A New Worldview @JACCJournals https://www.jacc.org/doi/10.1016/j.jchf.2024.11.014.
https://www.jacc.org/doi/10.1016/j.jacc. 2025.11.027?utm_medium ... jacc.org/doi/10.1016/j.jchf.2024.11.014 · May be an image of text.
... jacc.org/doi/10.1016/j.jacc.2024.11.014 https://jamanetwork.com/journals/jamacardiology/fullarticle/2826714 #Cardiology #FOAMed #MedEd ...
Not All Hospitalized Heart Failure Patients Are the Same: A New Worldview @JACCJournals https://www.jacc.org/doi/10.1016/j.jchf.2024.11.014.
Not All Hospitalized Heart Failure Patients Are the Same: A New Worldview @JACCJournals https://www.jacc.org/doi/10.1016/j.jchf.2024.11.014.
2024;doi:10.1016/j.jacc.2024.11.014. Published by: cardiology today logo. Sources/Disclosures. Source:.
... optimization in patients with heart failure" J Am Coll Cardiol 2024; DOI: 10.1016/j.jacc.2024.11.014. Comment. Please enable ...
Not All Hospitalized Heart Failure Patients Are the Same: A New Worldview @JACCJournals https://www.jacc.org/doi/10.1016/j.jchf.2024.11.014.
Not All Hospitalized Heart Failure Patients Are the Same: A New Worldview @JACCJournals https://www.jacc.org/doi/10.1016/j.jchf.2024.11.014.
Not All Hospitalized Heart Failure Patients Are the Same: A New Worldview @JACCJournals https://www.jacc.org/doi/10.1016/j.jchf.2024.11.014.
Not All Hospitalized Heart Failure Patients Are the Same: A New Worldview @JACCJournals https://www.jacc.org/doi/10.1016/j.jchf.2024.11.014.
https://www.jacc.org/doi/10.1016/j.jacc. 2025.11.027?utm_medium ... jacc.org/doi/10.1016/j.jchf.2024.11.014 · May be an image of text.
https://www.jacc.org/doi/10.1016/j.jacc. 2025.11.027?utm_medium ... jacc.org/doi/10.1016/j.jchf.2024.11.014 · May be an image of text.
Not All Hospitalized Heart Failure Patients Are the Same: A New Worldview @JACCJournals https://www.jacc.org/doi/10.1016/j.jchf.2024.11.014.
Not All Hospitalized Heart Failure Patients Are the Same: A New Worldview @JACCJournals https://www.jacc.org/doi/10.1016/j.jchf.2024.11.014.
Not All Hospitalized Heart Failure Patients Are the Same: A New Worldview @JACCJournals https://www.jacc.org/doi/10.1016/j.jchf.2024.11.014.
Not All Hospitalized Heart Failure Patients Are the Same: A New Worldview @JACCJournals https://www.jacc.org/doi/10.1016/j.jchf.2024.11.014.
Not All Hospitalized Heart Failure Patients Are the Same: A New Worldview @JACCJournals https://www.jacc.org/doi/10.1016/j.jchf.2024.11.014.
Not All Hospitalized Heart Failure Patients Are the Same: A New Worldview @JACCJournals https://www.jacc.org/doi/10.1016/j.jchf.2024.11.014.
Not All Hospitalized Heart Failure Patients Are the Same: A New Worldview @JACCJournals https://www.jacc.org/doi/10.1016/j.jchf.2024.11.014.
doi:10.1016/j.jacc.2023.10.039. doi:10.1016/j.ahj.2024.11.014. doi:10.1016/j.jacc.2009.07.057. #cholesterol · original sound - Kristen Blake ...
3423 Enhanced decongestive therapy in patients with ACH @JACCJournals https://www.jacc.org/doi/10.1016/j.jacc. 2024.01.029 Practical ...
AV
AM
HH
GH
PF
H循
TN
RG
BN
SA
A
D
D
DD
M
KE
YE
R
T
KO
A
GD
DP
NP
S
SM
M
JP
LF
RA
HP
木
L
JF
VJ
AB
AP
JP
HN
أا
循循
と
FZ
HB
DN
HE
U
N
JS
AA
MV
KF
DS
Y
DM
DA
AM
JB
PF
SZ
う
NF
PL
دس
NM
CF
AC
MT
OL
DS
FF
A
た
も
AM
MS
CG
VC
MM
RC
MG
NS
JJ
A
MM
DA
UK
CB
CB
CE
CÁ
AK
JR
C
MG
OH